---
layout: post
title: "Prospective Grant of Exclusive Patent Commercialization License: Human Monoclonal Antibodies That Broadly Target Coronaviruses"
date: 2026-02-05 18:57:16 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-23030
original_published: 2023-10-19 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of Exclusive Patent Commercialization License: Human Monoclonal Antibodies That Broadly Target Coronaviruses

**Published:** February 05, 2026 18:57 UTC
**Source:** Federal Register
**Original Published:** October 19, 2023 00:00 UTC
**Document Number:** 2023-23030

## Summary

The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Leyden Laboratories B.V., located at Emmy Noetherweg 2, 2333 BK Leiden, the Netherlands to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/10/19/2023-23030/prospective-grant-of-exclusive-patent-commercialization-license-human-monoclonal-antibodies-that)
- API: https://www.federalregister.gov/api/v1/documents/2023-23030

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
